# US 2013/0296312 A1 · Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296312 A1
- Document ID: US20130296312A1
- Status: Published application
- Kind: A1
- Application number: 13/920,153
- Filed: 2013-06-18
- Published: 2013-11-07
- Earliest claimed: 2009-06-05
- Assignees: Cephalon, Inc.
- Applicants: Cephalon, Inc.
- Inventors: Matthew A. Curry; Bruce D. Dorsey; Benjamin J. Dugan; Diane E. Gingrich; Eugen F. Mesaros; Karen L. Milkiewicz
- Web page: https://patentgrep.com/patent/US20130296312A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This application relates, in part, to compounds of the general Formula I and/or salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of inhibiting at least JAK2 in subjects in recognized need thereof for the treatment of diseases or disorders for which inhibition of at least JAK2 is indicated.

## Claims

### Claim 1

A method of inhibiting JAK2 in a subject in recognized need thereof, comprising administering a compound of Formula V:
or a salt thereof, wherein:
R3A, R4A, and R5A are each independently selected from H, OH, CN, NO2, halogen, (C1-C8)alkyl, (C1-C8)alkoxy, halo(C1-C4)alkyl, and halo(C1-C4)alkoxy;
R7A is selected from H and (C1-C8)alkyl;
R8 is selected from SO2R7A, NR7ACOR7A, (C2-C8)alkyl, (C1-C8)alkoxy, halo(C2-C4)alkyl, halo(C1-C4)alkoxy, (C3-C14)cycloalkyl, (C3-C14)cycloalkyloxy, (C3-C14)cycloalkyl(C1-C4)alkyl, (C3-C14)cycloalkyl(C1-C4)alkoxy, (C6-C10)aryl, (C6-C10)aryloxy, (C6-C10)aryl(C1-C4)alkyl, (C6-C10)aryl(C1-C4)alkoxy, (C2-C14)heterocycloalkyl, (C2-C14)heterocycloalkyloxy, (C2-C14)heterocycloalkyl(C1-C4)alkyl, (C2-C14)heterocycloalkyl(C1-C4)alkoxy, (C2-C9)heteroaryl, (C2-C9)heteroaryloxy, (C2-C9)heteroaryl(C1-C4)alkyl, and (C2-C9)heteroaryl(C1-C4)alkoxy, wherein each of the aforementioned groups may be optionally substituted with between one to four substituents;
R9 is selected from SO2R7A, POR7AR7A, NR7ASO2R7A, halo(C1-C4)alkyl, halogen, or (C2-C14)heterocycloalkyl optionally substituted with between one to four substituents;
R10 is selected from H and (C1-C4)alkyl optionally substituted with SO2(C1-C4)alkyl;
g is selected from 0, 1, 2, or 3; and
wherein said optional substituents are each independently selected from OH, CN, oxo, NO2, halogen, (C1-C8)alkyl, (C1-C8)alkoxy, hydroxy(C1-C4)alkyl, halo(C1-C4)alkyl, halo(C1-C4)alkoxy, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C4)alkyl, (C3-C14)cycloalkyloxy, (C3-C14)cycloalkyl(C1-C4)alkoxy, NR7AR7A, (C1-C4)alkyl-NRAR7A, (C6-C10)aryl, (C6-C10)aryl(C1-C4)alkyl, (C6-C10)aryloxy, (C6-C10)aryl(C1-C4)alkoxy, SO2R7A, (C1-C4)alkyl-SO2R7A, (C1-C4)alkyl-C(O)NR7AR7A, C(O)NR7AR7A, (C1-C4)alkyl-SO2NR7AR7A, SO2NR7AR7A, (C2-C14)heterocycloalkyl, (C2-C14)heterocycloalkyloxy, (C2-C14)heterocycloalkyl(C1-C4)alkyl, (C2-C14)heterocycloalkyl(C1-C4)alkoxy, (C2-C9)heteroaryl, (C2-C9)heteroaryloxy, (C2-C9)hetero aryl(C1-C4)alkyl, (C2-C9)heteroaryl(C1-C4)alkoxy, COR7A, (C1-C4)alkyl-COR7A, NR7ACOR7A, (C1-C4)alkyl-NR7ACOR7A, NR7ASO2R7A, (C1-C4)alkyl-NR7ASO2R7A, OSO2R7A, (C1-C4)alkyl-OSO2R7A, POR7AR7A, (C1-C4)alkyl-POR7AR7A, CO2R7A or (C1-C4)alkyl-CO2R7A,
wherein said compound or salt thereof preferentially inhibits the JAK2 enzyme in vitro.

### Claim 2 (depends on 1)

The method of claim 1 wherein the compound, or salt thereof, is selected from the following:
Structure
Name
4-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperidine-1-carboxylic acid tert- butyl ester
{8-[4-(Dimethyl-phosphinoyl)-phenyl]- [1,2,4]triazolo[1,5-a]pyridin-2-yl}-[3-(4- methyl-piperazin-1-yl)-phenyl]-amine
(3-Methanesulfonyl-phenyl)-[8-(4- methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine
(S)-1-(4-{3-[8-(4-Methanesulfonyl- phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2- ylamino]-phenyl}-piperazin-1-yl)-propan- 2-ol
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(4- morpholin-4-yl-piperidin-1-yl)-phenyl]- amine
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(4- methyl-piperazin-1-yl)-phenyl]-amine
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-(3- morpholin-4-yl-phenyl)-amine
4-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperazine-1-carboxylic acid tert- butyl ester
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-(3- piperidin-4-yl-phenyl)-amine
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(1- methyl-piperidin-4-yl)-phenyl]-amine
2-(4-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperazin-1-yl)-ethanol
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-(3- methoxy-phenyl)-amine
{3-[1-(2-Methanesulfonyl-ethyl)-piperidin- 4-yl]-phenyl}-[8-(4-methanesulfonyl- phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]- amine
N-{3-[(1,1-dioxidothiomorpholin-4- yl)methyl]phenyl}-8-[4- (methylsulfonyl)phenyl][1,2,4]triazolo[1,5- a]pyridin-2-amine
[3-(4-Methyl-piperazin-1-yl)-phenyl]-[8- (4-trifluoromethyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-{3-[4- (4-methyl-piperazin-1-yl)-piperidin-1-yl]- phenyl}-amine
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-(3- piperazin-1-yl-phenyl)-amine
(±)-cis-3-Hydroxy-4-{3-[8-(4- methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperidine-1-carboxylic acid tert- butyl ester
2-(4-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperidin-1-yl)-acetamide
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(4- methyl-piperazin-1-ylmethyl)-phenyl]- amine
N-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-acetamide
(R)-1-(4-{3-[8-(4-Methanesulfonyl- phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2- ylamino]-phenyl}-piperazin-1-yl)-propan- 2-ol
2-(4-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperazin-1-yl)-acetamide
1-(4-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperazin-1-yl)-2-methyl-propan- 2-ol
(±)-(cis)-4-{3-[8-(4-Methanesulfonyl- phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2- ylamino]-phenyl}-piperidin-3-ol
N-Methyl-N-(4-{2-[3-(4-methyl-piperazin- 1-yl)-phenylamino]-[1,2,4]triazolo[1,5- a]pyridin-8-yl}-phenyl)- methanesulfonamide
{3-[4-(3-Fluoro-propyl)-piperazin-1-yl]- phenyl}-[8-(4-methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine
[3-(4-Methyl-piperazin-1-yl)-phenyl]-{8- [4-(propane-2-sulfonyl)-phenyl]- [1,2,4]triazolo[1,5-a]pyridin-2-yl}-amine
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-(3- morpholin-4-ylmethyl-phenyl)-amine
(±)2-(cis)-3-Hydroxy-4-{3-[8-(4- methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperidin-1-yl)-acetamide
[8-(4-Fluoro-phenyl)-[1,2,4]triazolo[1,5- a]pyridin-2-yl]-[3-(4-methyl-piperazin-1- yl)-phenyl]-amine
{8-[4-(Dimethyl-phosphinoyl)-phenyl]- [1,2,4]triazolo[1,5-a]pyridin-2-yl}-{3-[1- (2-methanesulfonyl-ethyl)-piperidin-4-yl]- phenyl}-amine
1-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-4-methyl-piperazin-2-one
4-Ethyl-1-{3-[8-(4-methanesulfonyl- phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2- ylamino]-phenyl}-piperazin-2-one
[3-(4-Methyl-piperazin-1-yl)-phenyl]-(8- {4-[4-(4-methyl-piperazin-1-yl)-piperidin- 1-yl]-phenyl}-[1,2,4]triazolo[1,5- a]pyridin-2-yl)-amine
1-(3-{8-[4-(Dimethyl-phosphinoyl)- phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2- ylamino}-phenyl)-4-methyl-piperazin-2- one
1-(3-{8-[4-(Dimethyl-phosphinoyl)- phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2- ylamino}-phenyl)-4-ethyl-piperazin-2-one

### Claim 3

A method of treating a disease or disorder for which inhibition of at least JAK2 is indicated, comprising administering to subject in recognized need thereof a compound of Formula V
or a salt thereof, wherein:
R3A, R4A, and R5A are each independently selected from H, OH, CN, NO2, halogen, (C1-C8)alkyl, (C1-C8)alkoxy, halo(C1-C4)alkyl, and halo(C1-C4)alkoxy;
R7A is selected from H and (C1-C8)alkyl;
R8 is selected from SO2R7A, NR7ACOR7A, (C2-C8)alkyl, (C1-C8)alkoxy, halo(C2-C4)alkyl, halo(C1-C4)alkoxy, (C3-C14)cycloalkyl, (C3-C14)cycloalkyloxy, (C3-C14)cycloalkyl(C1-C4)alkyl, (C3-C14)cycloalkyl(C1-C4)alkoxy, (C6-C10)aryl, (C6-C10)aryloxy, (C6-C10)aryl(C1-C4)alkyl, (C6-C10)aryl(C1-C4)alkoxy, (C2-C14)heterocycloalkyl, (C2-C14)heterocycloalkyloxy, (C2-C14)heterocycloalkyl(C1-C4)alkyl, (C2-C14)heterocycloalkyl(C1-C4)alkoxy, (C2-C9)heteroaryl, (C2-C9)heteroaryloxy, (C2-C9)heteroaryl(C1-C4)alkyl, and (C2-C9)heteroaryl(C1-C4)alkoxy, wherein each of the aforementioned groups may be optionally substituted with between one to four substituents;
R9 is selected from SO2R7A, POR7AR7A, NR7ASO2R7A, halo(C1-C4)alkyl, halogen, or (C2-C14)heterocycloalkyl optionally substituted with between one to four substituents;
R10 is selected from H and (C1-C4)alkyl optionally substituted with SO2(C1-C4)alkyl;
g is selected from 0, 1, 2, or 3; and
wherein said optional substituents are each independently selected from OH, CN, oxo, NO2, halogen, (C1-C8)alkyl, (C1-C8)alkoxy, hydroxy(C1-C4)alkyl, halo(C1-C4)alkyl, halo(C1-C4)alkoxy, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C4)alkyl, (C3-C14)cycloalkyloxy, (C3-C14)cycloalkyl(C1-C4)alkoxy, NR7AR7A, (C1-C4)alkyl-NR7AR7A, (C6-C10)aryl, (C6-C10)aryl(C1-C4)alkyl, (C6-C10)aryloxy, (C6-C10)aryl(C1-C4)alkoxy, SO2R7A, (C1-C4)alkyl-SO2R7A, (C1-C4)alkyl-C(O)NR7AR7A, C(O)NR7AR7A, (C1-C4)alkyl-SO2NR7AR7A, SO2NR7AR7A, (C2-C14)heterocycloalkyl, (C2-C14)heterocycloalkyloxy, (C2-C14)heterocycloalkyl(C1-C4)alkyl, (C2-C14)heterocycloalkyl(C1-C4)alkoxy, (C2-C9)heteroaryl, (C2-C9)heteroaryloxy, (C2-C9)hetero aryl(C1-C4)alkyl, (C2-C9)heteroaryl(C1-C4)alkoxy, COR7A, (C1-C4)alkyl-COR7A, NR7ACOR7A, (C1-C4)alkyl-NR7ACOR7A, NR7ASO2R7A, (C1-C4)alkyl-NR7ASO2R7A, OSO2R7A, (C1-C4)alkyl-OSO2R7A, POR7AR7A, (C1-C4)alkyl-POR7AR7A, CO2R7A or (C1-C4)alkyl-CO2R7A,
wherein said compound or salt thereof preferentially inhibits the JAK2 enzyme in vitro.

### Claim 4 (depends on 3)

The method according to claim 3, wherein said compound or salt thereof is at least 20 fold more selective for the JAK2 enzyme over the JAK3 enzyme in vitro.

### Claim 5 (depends on 4)

The method of claim 4 wherein R3A, R4A, R5A, and R10 are each H and R9 is SO2R7A.

### Claim 6 (depends on 5)

The method of claim 5 wherein said compound, or salt thereof, is selected from
Structure
Name
4-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperidine-1-carboxylic acid tert- butyl ester
(3-Methanesulfonyl-phenyl)-[8-(4- methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine
(S)-1-(4-{3-[8-(4-Methanesulfonyl- phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2- ylamino]-phenyl}-piperazin-1-yl)-propan- 2-ol
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(4- morpholin-4-yl-piperidin-1-yl)-phenyl]- amine
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(4- methyl-piperazin-1-yl)-phenyl]-amine
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-(3- morpholin-4-yl-phenyl)-amine
4-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperazine-1-carboxylic acid tert- butyl ester
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-(3- piperidin-4-yl-phenyl)-amine
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(1- methyl-piperidin-4-yl)-phenyl]-amine
2-(4-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperazin-1-yl)-ethanol
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-(3- methoxy-phenyl)-amine
{3-[1-(2-Methanesulfonyl-ethyl)-piperidin- 4-yl]-phenyl}-[8-(4-methanesulfonyl- phenyl)-[1,2,4]triazolo[1,5-a]pyndin-2-yl]- amine
N-{3-[(1,1-dioxidothiomorpholin-4- yl)methyl]phenyl}-8-[4- (methylsulfonyl)phenyl][1,2,4]triazolo[1,5- a]pyridin-2-amine
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-{3-[4- (4-methyl-piperazin-1-yl)-piperidin-1-yl]- phenyl}-amine
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-(3- piperazin-1-yl-phenyl)-amine
(±)-cis-3-Hydroxy-4-{3-[8-(4- methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperidine-1-carboxylic acid tert- butyl ester
2-(4-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperidin-1-yl)-acetamide
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(4- methyl-piperazin-1-ylmethyl)-phenyl]- amine
N-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-acetamide
(R)-1-(4-{3-[8-(4-Methanesulfonyl- phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2- ylamino]-phenyl}-piperazin-1-yl)-propan- 2-ol
2-(4-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperazin-1-yl)-acetamide
1-(4-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperazin-1-yl)-2-methyl-propan- 2-ol
(±)-(cis)-4-{3-[8-(4-Methanesulfonyl- phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2- ylamino]-phenyl}-piperidin-3-ol
{3-[4-(3-Fluoro-propyl)-piperazin-1-yl]- phenyl}-[8-(4-methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine
[3-(4-Methyl-piperazin-1-yl)-phenyl]-{8- [4-(propane-2-sulfonyl)-phenyl]- [1,2,4]triazolo[1,5-a]pyridin-2-yl}-amine
[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-yl]-(3- morpholin-4-ylmethyl-phenyl)-amine
(±)2-(cis)-3-Hydroxy-4-{3-[8-(4- methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-piperidin-1-yl)-acetamide
1-{3-[8-(4-Methanesulfonyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2-ylamino]- phenyl}-4-methyl-piperazin-2-one
4-Ethyl-1-{3-[8-(4-methanesulfonyl- phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2- ylamino]-phenyl}-piperazin-2-one
